- Home
- NCPL vs ENVB Comparison
NCPL vs ENVB Comparison
Compare NCPL & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCPL | ENVB |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | NCPL | ENVB |
|---|---|---|
| Price | $0.43 | $3.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 148.7K | ★ 634.4K |
| Earning Date | 03-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | $739.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.31 | $0.56 |
| 52 Week High | $8.75 | $13.25 |
Technical Indicators
Market Signals| Indicator | NCPL | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 73.41 |
| Support Level | $0.37 | $0.81 |
| Resistance Level | $0.60 | $4.48 |
| Average True Range (ATR) | 0.04 | 0.33 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 70.38 | 50.27 |
Price Performance
Historical ComparisonAbout NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.